Related Experiment Video

Updated: Aug 2, 2026

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
06:05

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins

Published on: September 30, 2014

A clinical evaluation of pivampicillin in childhood pneumonia

A A Khan

    The Journal of International Medical Research
    |January 1, 1977
    PubMed

    Insights

    Pivampicillin suspension effectively treated childhood pneumonias in a clinical trial. The drug showed minimal side effects, with only one child experiencing diarrhea, indicating its safety and efficacy in pediatric patients.

    Area of Science:

    • Pediatric Medicine
    • Clinical Pharmacology

    Background:

    • Childhood pneumonia remains a significant health concern globally.
    • Effective and safe antibiotic treatments are crucial for managing pediatric respiratory infections.

    Purpose of the Study:

    • To evaluate the therapeutic efficacy and safety of pivampicillin suspension in treating clinical pneumonias in children.
    • To assess adverse drug reactions associated with pivampicillin treatment in a pediatric cohort.

    Main Methods:

    • A clinical trial involving 20 children diagnosed with clinical pneumonias.
    • Treatment administered with pivampicillin suspension at a dosage of 175 mg three times daily.
    • Post-discharge follow-up examinations conducted 7-10 days after hospital discharge.

    Main Results:

    • Pivampicillin demonstrated therapeutic effectiveness in treating childhood pneumonias.
    • Adverse drug toxicity was not significant, as indicated by biomedical investigations.
    • Only one child (5%) experienced diarrhea as a side effect during the treatment period.

    Conclusions:

    • Pivampicillin suspension is a therapeutically effective option for childhood pneumonias.
    • The drug exhibits a favorable safety profile with minimal adverse effects in pediatric patients.
    • Further research may explore pivampicillin's role in broader pediatric infectious disease management.

    More Related Videos

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

    Published on: January 22, 2021

    Related Concept Videos

    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
    Atypical Pneumonia01:14

    Atypical Pneumonia

    Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
    Viral Meningitis01:18

    Viral Meningitis

    Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...